China Medical University Hospital has developed the "Brain Trodat: Tc-99m TRODAT-1 AI-Assisted Platform," utilizing a closed-loop artificial intelligence algorithm. This platform can provide doctors with the highest-quality imaging of striatal dopamine transporter uptake and Visual Scale (VS) scores in just six seconds, delivering faster and more accurate medical services for patients. With the help of this system, clinicians can observe the activity of dopamine transporters in the patient's brain striatum, reflecting the severity of central nervous system movement disorders. The accuracy rate (ACC) between adjacent rating levels in the model has reached 96.05%.
Decoding Dopamine Transporter Activity: AI Provides Accurate Predictions for Early Prevention and Treatment
The core technology of this platform lies in observing the activity of dopamine transporters in the striatum through single-photon emission computed tomography (SPECT) scans. Key technological highlights include:
Automated Basal Ganglia Selection: Using deep learning algorithms, the system selects the image with the highest Tc-99m TRODAT-1 uptake and provides a suggestion for the physician.
Automated SUR Calculation: By moving the basal ganglia mask, the system automatically calculates the Specific Uptake Ratio (SUR) values.
AI Interpretation of Dopamine Transporter Activity Classification: The AI analyzes the distribution and activity of dopamine transporters in the brain and provides corresponding classifications, offering physicians more objective diagnostic references and aiding in the formulation of treatment plans.
Enhanced Diagnostic Efficiency: The platform significantly reduces the diagnostic process, allowing patients to receive treatment earlier.
Microservices Architecture: The platform’s interface is user-friendly and can be quickly deployed on various systems, creating a one-stop service platform.
From Laboratory to Clinical Use: The "Brain Trodat" Platform is Ready for Commercialization
As Taiwan is projected to become a super-aged society by 2025, with over 20% of the population being elderly, the number of patients with central nervous system movement disorders is steadily increasing. Traditional medical evaluation methods are time-consuming, but this AI platform, with its precise analysis, drastically shortens diagnostic times, allowing patients to receive earlier diagnoses and treatments. The platform has completed preliminary validation with an accuracy rate exceeding 90%. The team is actively working on the commercialization of the "Brain Trodat" platform through a B2B model, integrating the platform with nuclear medicine drugs to provide a more comprehensive solution. Future plans include optimizing the platform’s features and expanding its applications, with the goal of improving the quality of life for more patients suffering from central nervous system-related movement disorders.
Resource (mandarin): AI解密多巴胺轉運體 6秒快篩中樞神經系統動作障礙！
